Topiramate add-on treatment in schizophrenia: A randomised, double-blind, placebo-controlled clinical trial

Journal of Psychopharmacology

Volumn 23, Issue 2, 2009, Pages 157-162

  Afshar, H ^a   Roohafza, H ^b   Mousavi, G ^a   Golchin, S ^a   Toghianifar, N ^b   Sadeghi, M ^b   Talaei, M ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; PANSS; Schizophrenia; Topiramate

Indexed keywords

CLOZAPINE; PLACEBO; TOPIRAMATE; ANTICONVULSIVE AGENT; ANTIOBESITY AGENT; DRUG DERIVATIVE; FRUCTOSE; NEUROLEPTIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERSALIVATION; MALE; PARESTHESIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT REDUCTION; ADOLESCENT; DRUG COMBINATION; MIDDLE AGED; PSYCHOLOGY; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 67649177544     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089816     Document Type: Article

References (25)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, fourth ed. text revision. Washington, DC: American Psychiatric Association.
2. Arone D, (2005) Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 4.
3. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH, (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11: 722 - 733.
4. Csernansky JG, Bardgett ME, (1998) Limbic-cortical neuronal damage and the pathophysiology of schizophrenia. Schizophr Bull 24: 231 - 248.
5. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM, (1989) A ?glutamatergic hypothesis? of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12: 1 - 13.
6. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J, (2002) Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol 449: 121 - 125.
7. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI, (2001) Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 24: 290 - 294.
8. Dursun SM, Deakin JFW, (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 15: 297 - 301.
9. Eltayb A, Wadenberg ML, Schilstrom B, Svensson TH, (2005) Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride. Naunyn Schmiedebergs Arch Pharmacol 372: 195 - 202.
10. Grace AA, (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1 - 24.
11. Harrison PJ, Mclaughlin D, Kerwin RW, (1991) Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 337: 450 - 452.
12. Javitt DC, Zukin SR, (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301 - 1308.
13. Kay SR, Fiszbein A, Opler LA, (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261 - 276.
14. Ko YH, Joe SH, Jung IK, Kim SH, (2005) Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28: 169 - 175.
15. Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U, (2007) How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem Int 50: 291 - 301.
16. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS, (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199 - 214.
17. Millson RC, Owen JA, Lorberg GW, Tackaberry L, (2002) Topiramate for refractory schizophrenia. Am J Psychiatry 159: 675.
18. O'Donnell P, Grace AA, (1998) Dysfunctions in multiple interrelated systems as the neurological bases of schizophrenic symptom clusters. Schizophr Bull 24: 267 - 283.
19. Quetelet LA, (1869) Physique Social, vol. 2C. Muquardt: Brussels.
20. Tamminga CA, Cascella N, Fakouhi TD, Herting RL, (1992) Enhancement of NMDA-mediated transmission in schizophrenia. Effects of milacemide. In: HY Meltzer, (ed). Novel Antipsychotic Drugs. New york: Raven Press Ltd.
21. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, Putkonen H, Takala P, Mehtonen OP, Puck M, Oksanen J, Koskelainen P, Joffe G, Aer J, Hallikainen T, Ryynanen OP, Tupala E, (2005) Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66: 1012 - 1015.
22. Ulas J, Cotman CW, (1993) Excitatory amino acid receptors in schizophrenia. Schizophr Bull 19: 105 - 117.
23. Werneke U, Taylor D, Sanders TA, (2002) Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 17: 145 - 160.
24. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH, (2000) Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41: S17 - S20.
25. Zheng HY, Patterson C, Berthoud HR, (2002) Behavioral analysis of anorexia produced by hindbrain injections of AMPA receptor antagonist NBQX in rats. Am J Physiol 282: 147 - 155.